ArticleClinical journal of oncology nursing2016

Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.

Wendy Pritchett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.